Direkt zum Inhalt
  • ELGA weltweit
  • Über ELGA
    • Über ELGA
    • Karriere
    • Veranstaltungen
  • Service
    • Laborplanung
    • Ein Produkt registrieren
    • Register Your Product (USA & Canada Only)
  • Kontakt
  • U.S.A.
  • U.K.
  • España
  • France
  • Italia
  • Brasil
  • 日本
  • 中国
Startseite ELGA LabWater
  • Produkte
    • PURELAB
    • CENTRA
    • MEDICA
    • BIOPURE
    • Komplette Produktpalette
  • Anwendungen
    • Allgemeiner Laborwasserbedarf
    • Atomspektroskopie
    • Elektrochemie
    • Flüssigchromatographie
    • Gaschromatographie
    • Genetik
    • Immunchemie
    • Klinische Biochemie
    • Massenspektrometrie
    • Mikrobiologische Analyse
    • Spektrophotometrie
    • Zellkulturen
  • Technologien
    • Aktivkohle
    • Elektroentionisierung (EDI)
    • Filtration
    • Ionenaustausch
    • PureSure
    • Ultraviolettes Licht (UV)
    • Umkehrosmose (RO)
  • Verunreinigungen im Wasser
    • Anorganische Verbindungen
    • Gelöste Gase
    • Mikroorganismen und Bakterien
    • Organische Verbindungen
    • Partikel
  • Wissen
    • Blog
    • Referenzen
    • Reinstwasser
    • Whitepaper rund um Laborwasser
  • Produkte
    • PURELAB
    • CENTRA
    • MEDICA
      • Hubgrade
      • MEDICA BIOX
    • BIOPURE
    • Komplette Produktpalette
      • PURELAB® Classic
  • Anwendungen
    • Allgemeiner Laborwasserbedarf
    • Atomspektroskopie
    • Elektrochemie
    • Flüssigchromatographie
      • Hochleistungsflüssigkeitschromatographie (HPLC)
    • Gaschromatographie
    • Genetik
    • Immunchemie
    • Klinische Biochemie
    • Massenspektrometrie
    • Mikrobiologische Analyse
    • Spektrophotometrie
    • Zellkulturen
  • Technologien
    • Aktivkohle
    • Elektroentionisierung (EDI)
    • Filtration
    • Ionenaustausch
    • PureSure
    • Ultraviolettes Licht (UV)
    • Umkehrosmose (RO)
  • Verunreinigungen im Wasser
    • Anorganische Verbindungen
    • Gelöste Gase
    • Mikroorganismen und Bakterien
    • Organische Verbindungen
    • Partikel
  • Wissen
    • Blog
      • Analytical Chemistry
      • Clinical & Pharma
      • Cool Science
      • Environment and sustainability
      • Life in the lab
      • Purelab product design
      • Science of the future
      • Water Purity
      • Water in the lab
    • Referenzen
      • Abbott Diagnostics entscheidet sich für ELGA MEDICA Systeme in Südasien
      • Beam Me Up, Scotty: PURELAB® Option Q Delivers Essential Ultra Pure Water
      • Argenta chooses DKSH New Zealand to deliver Ultrapure water in Animal Pharma
      • Clean Water for a Clean Future
      • LS Scientific & ELGA deliver UltraPure water to the NAFDAC Laboratory
      • Lifebrain Group chooses ELGA as water partner for new modern 24/7 PCR-COVID-19 laboratory in Vienna, Austria.
      • Critital Tests Benefit from PURELAB® Option Reliable Pure Water
      • DASA: Das größte medizinische Diagnostikunternehmen in Brasilien
      • ELGA unterstützt Immunserologie-Labore bei der Maximierung der Betriebszeit
      • Fondazione Telethon Continues to Choose ELGA Labwater as a Trusted Partner
      • Bedeutung von Reinstwasser Typ 1+ für die Entwicklung von Generika
      • MEDICA® Pro ausgewählt für Siemens ADVIA® Analysatoren im City General Hospital
      • Optimale Wasserqualität für mikrobiologische Forschung und Lehre
      • PURELAB® Option R Guarantees Pure Water for Leading Microfluidics Technology
      • PURELAB® Pulse Delivers Reliable Water Quality and Quantity for a Wide Range of Applications
      • PURELAB® flex: ein ideales Trainingssystem für heutige Forschungsverfahren
      • Powering Cutting-Edge Gene Research
      • Sichere Reinstwasserversorgung für präzise Produkttests
      • Zentrale Reinstwasser-Aufbereitung für Analyser
      • ELGA LabWater and Beckman Coulter Join Forces
      • Applied New Technologies Department Improves ICP, IC & HPLC Sample Turnaround Times with PURELAB®
      • Die Geheimnisse der Antarktis mithilfe von Reinstwasser entschlüsseln
      • Advancing Genetic Technologies
      • Cross Infection Control: Pure and Simple
      • Researching effective new ways to prevent cardiovascular disease at the University of Columbia
    • Reinstwasser
    • Whitepaper rund um Laborwasser
      • Klinische Risiken reduzieren
      • Nachhaltigkeit
  • U.S.A.
  • U.K.
  • España
  • France
  • Italia
  • Brasil
  • 日本
  • 中国
  • Datenschutzerklärung
  • Geschäftsbedingungen
  • Globale Entsprechenserklärungen
  • Patente
  • Impressum
  • Startseite
  • New ‘designer drug’ identified in e-cigarettes
Clinical & Pharma
Cool Science

New ‘designer drug’ identified in e-cigarettes

24 Okt. 2022
- by Dr Alison Halliday

New 'designer drug' identified in e-cigarettes

A novel synthetic cannabinoid in seized e-cigarette liquid samples may pose a threat to the health of drug users.

Synthetic cannabinoids are a novel class of ‘designer drugs’ that first emerged in the late 2000s. A wide variety of new synthetic cannabinoids have since been identified in hundreds of different products around the world. Because of their rapid emergence, the detection and monitoring of this class of abused drugs remains a challenge, particularly as makers change their formulations frequently.

These illicit substances are often sold as ‘legal’ replacements for cannabis because they work on the same cannabinoid receptors in the brain as tetrahydrocannabinol (or THC), the main psychoactive ingredient in cannabis. However, many of the synthetic cannabinoids sold on the drug market are more potent than THC – which could help to explain why their harmful effects, such as severe and fatal poisoning, appear to be more common. People may also be exposed to large doses of these substances, which further increases the risk of their usage.

The potential for harmful effects posed by synthetic cannabinoids highlights the importance of identifying novel compounds entering the market to enable the monitoring of any adverse effects associated with their use.

In recent years, cannabinoids from the indazole-3-carboxamide family have emerged as the most frequently detected synthetic cannabinoids. So far, approximately 50 derivatives have been identified worldwide.

Forensic analyses

In a new study, published in Forensic Science International, scientists identify a novel indazole-3-carboxamide synthetic cannabinoid in seized e-cigarette liquids.1

The researchers analysed six samples seized from a suspect who was arrested for buying and selling e-cigarette liquid containing synthetic cannabinoids. They initially used gas chromatography-mass spectrometry (GC-MS) screening, isolating an unknown brominated compound. After a series of complicated analyses, they then determined the chemical structure of the novel compound using Fourier-transform infrared spectroscopy (FT-IR), high-performance liquid chromatography-high resolution quadruple-mass spectrometry (HPLC-QTOF-MS/MS) and nuclear magnetic resonance spectrometry (NMR).

The team then used quantitative NMR and GC-MS to determine the concentration of the compound in the seized e-cigarette liquid samples – which ranged between 2228-4203 mg/L.

For these experiments, the researchers used deionised water generated from an ELGA PURELAB® Chorus laboratory water purification system to minimise the risk of introducing contaminants that may affect their results.

Comprehensive characterisation

In this study, researchers identify a novel synthetic cannabinoid in the indazole-3-carboxamide family, which they newly named as ADB-BRINACA, in seized e-cigarette liquid samples.

While the potency of this novel compound is currently unknown, the considerable amount of ADB-BRINACA detected in these samples indicates that it may pose a threat to the health of drug users. It will now be important to determine the binding affinity of this synthetic cannabinoid on cannabinoid receptors and its biological activities.

The method presented in this study could be a useful technique for determining the concentration of ADB-BRINACA in test samples, in the absence of reference material.

Why choose ELGA LabWater

ELGA’s expert engineers, chemists and scientists are at the forefront of technological innovation. We continue to introduce game-changing features to the laboratory water market.



Reference:

  1. Choi, H. et al. Identification of a novel bromoindazole synthetic cannabinoid analogue in seized e-cigarette liquid: ADB-BRINACA. Forensic Sci. Int. 2022;338:111385 https://doi.org/10.1016/j.forsciint.2022.111385

 

Dr Alison Halliday
After completing an undergraduate degree in Biochemistry & Genetics at Sheffield University, Alison was awarded a PhD in Human Molecular Genetics at the University of Newcastle. She carried out five years as a Senior Postdoctoral Research Fellow at UCL, investigating the genes involved in childhood obesity syndrome. Moving into science communications, she spent ten years at Cancer Research UK engaging the public about the charity’s work. She now specialises in writing about research across the life sciences, medicine and health.








 



 

  • Anfrage
  • Angebot anfordern
  • Produkt-Vorführung buchen
  • Einen Ansprechpartner finden

Anfrage

Ich habe die Datenschutzerklärung gelesen und verstanden

Angebot anfordern

Ich habe die Datenschutzerklärung gelesen und verstanden

Produkt-Vorführung buchen

Ich habe die Datenschutzerklärung gelesen und verstanden

Call us

Can't find what you are looking for?

Support Number
+44 (0)20 3567 7300
United Kingdom Sales
+44 (0)1628 879 704
United States of America Sales
+1 877-315-3542
France Sales
+33 1 40 83 65 00
China Sales
+86 400-616-8882

 

ELGA LabWater US Headquarters

ELGA LabWater
Veolia Water Technologies Deutschland GmbH
Lückenweg 5
29227 Celle
T: +49 (0) 51 41 803 0
F: +49 (0) 51 41 803 384

ELGA LabWater Deutschland

ELGA LabWater
Veolia Water Technologies Deutschland GmbH
Lückenweg 5
29227 Celle
T: +49 (0) 51 41 803 0
F: +49 (0) 51 41 803 384

Referenzen

  • Abbott Diagnostics
  • DASA Medical Diagnostics
  • NeoDIN Medical Institute
  • North Staffordshire NHS Trust
  • Berufskolleg Olsberg

Ressourcen

  • Erfahren Sie mehr über Reinstwasser
  • Whitepaper rund um Laborwasser
  • Technologien zur Wasseraufbereitung
  • Laboranwendungen
  • Verunreinigungen im Wasser

Blogs

  • Latest Blog
  • Water Purity - Different Types of Pure Water
  • What is Clinical Laboratory Reagent Water (CLSI)?
  • What is Total Organic Carbon (TOC)?
  • Sprache
    • Deutsch
    • English
    • Español
    • Français
    • Italiano
    • Português
    • 日本語
    • 中文
  • Andere Veolia Webseiten
    • Veolia
    • Veolia Foundation
    • Veolia Water Technologies

© VWS (UK) Ltd, handelnd als ELGA LabWater.2023- Alle Rechte vorbehalten.
ELGA ist der globale Markenname von Veolia für Laborwasser.

  • Datenschutzerklärung
  • Geschäftsbedingungen
  • Globale Entsprechenserklärungen
  • Patente
  • Impressum
Elga Veolia
TOP

© 2017 ELGA Veolia